GALT Gene: Galactose-1-Phosphate Uridylyltransferase

Genetic variants in GALT cause classic galactosemia, a disorder of galactose metabolism.

Gene Information Card

Symbol GALT
Full Name galactose-1-phosphate uridylyltransferase
Gene Type protein coding
Chromosomal Location 9p13.3
NCBI Gene ID 2592 ncbi.nlm.nih.gov/gene/2592
Ensembl ID ENSG00000113924
UniProt ID P07902
OMIM ID 606999
HGNC ID 4155
Aliases GALT, GalT, galactosemia

Description

The GALT gene encodes galactose-1-phosphate uridylyltransferase, a key enzyme in the Leloir pathway of galactose metabolism. This enzyme catalyzes the conversion of UDP-glucose and galactose-1-phosphate to UDP-galactose and glucose-1-phosphate. Defects in this enzyme lead to classic galactosemia, an autosomal recessive metabolic disorder characterized by an inability to metabolize galactose properly, resulting in toxic accumulation of galactose-1-phosphate and other metabolites.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Classic Galactosemia Loss-of-function mutations in GALT lead to deficiency of galactose-1-phosphate uridylyltransferase, causing accumulation of galactose-1-phosphate and galactitol, leading to toxic effects in liver, kidney, and brain. OMIM 230400; ClinVar
Galactosemia, Duarte Variant Specific variants (e.g., p.Asn314Asp) reduce enzyme activity partially, causing a milder form of galactosemia with variable clinical presentation. ClinVar; PMID: 23430936
Galactosemia, Clinical Variants Other rare variants (e.g., p.Ser135Leu, p.Gln188Arg) cause varying degrees of enzyme deficiency, leading to classic or variant galactosemia. ClinVar; PMID: 23430936

Expression Profile

Tissue Expression
Tissue nTPM level
Liver 15.2 Medium
Kidney 10.5 Medium
Small Intestine 8.3 Low
Pancreas 6.1 Low
Brain 3.2 Low
Cell Line Expression
Cell Line nTPM Notes
HepG2 (liver) 12.4 High expression
A549 (lung) 5.6 Moderate
MCF7 (breast) 3.1 Low
K562 (leukemia) 2.0 Low
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
p.Gln188Arg Missense ~70% of classic galactosemia alleles in Caucasian populations Severe enzyme deficiency, classic galactosemia
p.Lys285Asn Missense Common in African American populations Severe enzyme deficiency, classic galactosemia
p.Ser135Leu Missense Rare Moderate enzyme deficiency, variant galactosemia
p.Asn314Asp Missense Common in Duarte variant Partial enzyme activity, milder phenotype
c.820+1G>A Splice site Rare Splicing defect, severe enzyme deficiency
Mutation functional classification

Loss of Function (LOF)

Most pathogenic GALT mutations are loss-of-function, leading to reduced or absent enzyme activity, causing galactosemia.

Gain of Function (GOF)

No gain-of-function mutations have been reported for GALT.

Dominant Negative (DN)

GALT is a homodimer; some missense mutations may exert a dominant-negative effect by interfering with the wild-type subunit, but this is not well established.

Gene Ontology (GO)

• galactose-1-phosphate uridylyltransferase activity • UDP-glucose:galactose-1-phosphate uridylyltransferase activity
• metal ion binding • galactose metabolic process
• carbohydrate metabolic process

Pathways

• Galactose metabolism (KEGG: hsa00052)
• Leloir pathway

Protein Summary

The GALT protein is a homodimeric enzyme of 387 amino acids (43 kDa) that catalyzes the second step of the Leloir pathway. It requires a divalent metal ion (e.g., zinc) for activity. The enzyme has two domains: an N-terminal domain involved in substrate binding and a C-terminal domain that interacts with UDP-glucose. Mutations affecting the active site or dimerization lead to enzyme deficiency and galactosemia.

Related Products

Product name Cat.No. Species Gene ID
GALT Knockout HEK293 Cell Line EDJ-KQ17877 Human 2592 Details Get a Quote
GALT Knockout HeLa Cell Line EDJ-KQ53303 Human 2592 Details Get a Quote
GALT Knockout A-549 Cell Line EDJ-KQ61787 Human 2592 Details Get a Quote
GALT Knockout HCT 116 Cell Line EDJ-KQ70268 Human 2592 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: